Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1995 Dec;79(12):1074–1077. doi: 10.1136/bjo.79.12.1074

Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.

N Ohguro 1, M Matsuda 1, Y Ohashi 1, M Fukuda 1
PMCID: PMC505343  PMID: 8562538

Abstract

BACKGROUND--Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. CONCLUSION--These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.

Full text

PDF
1074

Images in this article

1076Image
on p.1076

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akagi Y., Yajima Y., Kador P. F., Kuwabara T., Kinoshita J. H. Localization of aldose reductase in the human eye. Diabetes. 1984 Jun;33(6):562–566. doi: 10.2337/diab.33.6.562. [DOI] [PubMed] [Google Scholar]
  2. Bourne W. M., Brubaker R. F., O'Fallon W. M. Use of air to decrease endothelial cell loss during intraocular lens implantation. Arch Ophthalmol. 1979 Aug;97(8):1473–1475. doi: 10.1001/archopht.1979.01020020135009. [DOI] [PubMed] [Google Scholar]
  3. Datiles M. B., Kador P. F., Kashima K., Kinoshita J. H., Sinha A. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs. Invest Ophthalmol Vis Sci. 1990 Nov;31(11):2201–2204. [PubMed] [Google Scholar]
  4. Foulks G. N., Thoft R. A., Perry H. D., Tolentino F. I. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. Arch Ophthalmol. 1979 Jun;97(6):1076–1078. doi: 10.1001/archopht.1979.01020010530002. [DOI] [PubMed] [Google Scholar]
  5. Kern T. S., Engerman R. L. Distribution of aldose reductase in ocular tissues. Exp Eye Res. 1981 Aug;33(2):175–182. doi: 10.1016/s0014-4835(81)80066-8. [DOI] [PubMed] [Google Scholar]
  6. Ludvigson M. A., Sorenson R. L. Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes. 1980 Jun;29(6):450–459. doi: 10.2337/diab.29.6.450. [DOI] [PubMed] [Google Scholar]
  7. Matsuda M., Awata T., Ohashi Y., Inaba M., Fukuda M., Manabe R. The effects of aldose reductase inhibitor on the corneal endothelial morphology in diabetic rats. Curr Eye Res. 1987 Feb;6(2):391–397. doi: 10.3109/02713688709025192. [DOI] [PubMed] [Google Scholar]
  8. Matsuda M., Ohguro N., Ishimoto I., Fukuda M. Relationship of corneal endothelial morphology to diabetic retinopathy, duration of diabetes and glycemic control. Jpn J Ophthalmol. 1990;34(1):53–56. [PubMed] [Google Scholar]
  9. Matsuda M., Suda T., Manabe R. Quantitative analysis of endothelial mosaic pattern changes in anterior keratoconus. Am J Ophthalmol. 1984 Jul 15;98(1):43–49. doi: 10.1016/0002-9394(84)90187-9. [DOI] [PubMed] [Google Scholar]
  10. Meyer L. A., Ubels J. L., Edelhauser H. F. Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment. Invest Ophthalmol Vis Sci. 1988 Jun;29(6):940–948. [PubMed] [Google Scholar]
  11. O'Neal M. R., Polse K. A. Decreased endothelial pump function with aging. Invest Ophthalmol Vis Sci. 1986 Apr;27(4):457–463. [PubMed] [Google Scholar]
  12. Ohashi Y., Awata T., Sogo S., Ohira M., Matsuda M., Fukuda M., Manabe R. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation. J Ocul Pharmacol. 1989 Winter;5(4):325–328. doi: 10.1089/jop.1989.5.325. [DOI] [PubMed] [Google Scholar]
  13. Ohashi Y., Matsuda M., Hosotani H., Tano Y., Ishimoto I., Fukuda M., Manabe R. Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. Am J Ophthalmol. 1988 Mar 15;105(3):233–238. doi: 10.1016/0002-9394(88)90001-3. [DOI] [PubMed] [Google Scholar]
  14. Rao G. N., Aquavella J. V., Goldberg S. H., Berk S. L. Pseudophakic bullous keratopathy. Relationship to preoperative corneal endothelial status. Ophthalmology. 1984 Oct;91(10):1135–1140. [PubMed] [Google Scholar]
  15. Rao G. N., Shaw E. L., Arthur E. J., Aquavella J. V. Endothelial cell morphology and corneal deturgescence. Ann Ophthalmol. 1979 Jun;11(6):885–899. [PubMed] [Google Scholar]
  16. Schultz R. O., Matsuda M., Yee R. W., Edelhauser H. F., Schultz K. J. Corneal endothelial changes in type I and type II diabetes mellitus. Am J Ophthalmol. 1984 Oct 15;98(4):401–410. doi: 10.1016/0002-9394(84)90120-x. [DOI] [PubMed] [Google Scholar]
  17. Yee R. W., Matsuda M., Kern T. S., Engerman R. L., Edelhauser H. F. Corneal endothelial changes in diabetic dogs. Curr Eye Res. 1985 Jul;4(7):759–766. doi: 10.3109/02713688509020031. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES